Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the eme
Shares in Sanofi were on the slide this morning after the drugmaker revealed that one of its top pipeline prospects – selective oestrogen receptor degrader (SERD) amcenestrant – stumbled in
The FDA has cleared AstraZeneca and Merck & Co's Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over pretenders to its PARP inhibitor crown.
The results of Gilead's much-anticipated TROPiCS-02 study of Trodelvy are in, and while the company says top-line data are positive, its guarded stance has rung some alarm bells.
Already making inroads as a treatment for HER2-positive breast cancer, AstraZeneca and Daiichi Sankyo's Enhertu has now shown efficacy in tumours that express lower levels of HER2 – potenti
The FDA will deliver a verdict on AstraZeneca’s PARP inhibitor Lynparza as an adjuvant treatment for breast cancer in the first quarter of next year, after granting the application a priori